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Accepted 25 February 2020Animal models of chronic disease are continuously being refined and have evolved with the
goal of increasing the translation of results to human populations. Examples of this
progress include transgenic models and germ-free animals conventionalized with human
microbiota. The gut microbiome is involved in the etiology of several chronic diseases.
Therefore, consideration of the experimental conditions that may affect the gut
microbiome in preclinical disease is very important. Of note, diet plays a large role in
shaping the gut microbiome and can be a source of variation between animal models and
human populations. Traditionally, nutrition researchers have focused on manipulating the
macronutrient profile of experimental diets to model diseases such as metabolic syndrome.
However, other dietary components found in human foods, but not in animal diets, can
have sizable effects on the composition and metabolic capacity of the gut microbiome and,
as a consequence, manifestation of the chronic disease being modeled. The purpose of this
review is to describe how food matrix food components, including diverse fiber sources,
oxidation products from cooking, and dietary fat emulsifiers, shape the composition of the
gut microbiome and influence gut health.
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The role of the gut microbiome in health and disease has
received considerable attention over the last decade. The gut
microbiome is the most diverse and complex community of
microorganisms in the body, consisting of more than a
thousand bacterial species [1]. The relationships between
these bacteria and the host are generally commensal or
symbiotic in nature. For instance, it is estimated that humans
obtain approximately 10% of their daily energy intake from
short-chain fatty acids (SCFAs) derived from microbial fer-
mentation [2]. Alternatively, many studies have been per-
formed examining the relationship between the gut
microbiome and health, and it is now known that dysbiosis
of the gut microbiome is associated with numerous diseases,
including metabolic syndrome, inflammatory bowel syn-
drome, and colorectal cancer [3-5]. Much of this pioneering
work has been performed using preclinical models. Rodent
models of human disease have been invaluable for mecha-
nistic studies, in part because experimental variation can be
tightly controlled among investigations. The use of inbred
rodent strains, standardized environments, and semipurified
diets has helped reduce experimental variability and allowed
for investigations from different laboratories to be compared
and replicated. Moreover, gnotobiotic or antibiotic depletion
protocols can be used along with microbiota transfer to
investigate whether the gut microbiome is correlative or
causative in disease models.
An assumption in the use of animal models in biomedical
and nutrition research is that the results will be of value to
human well-being [6]. Yet, it is estimated that up to 80% of
therapeutics fail in humans after being previously shown to
be safe and (or) effective in rodents [7]. Two possible
explanations for this discordance were suggested by Ioannidis
[6]. The first may lie in fundamental physiological differences
between the animal model and humans, both in healthy and
in diseased conditions. The second reason interventions may
work in one species but not in another may be a result of
study design and/or publishing bias toward negative results.
In terms of study design, factors such as dose and duration
may differ significantly between species. Brown et al sug-
gested that a 4-week study in rats with a lifespan of 2.5 years
would be similar to a 2-year study in humans due to lifespan
differences [14]. Because most nutrition intervention studies
in the literature are at least 4 weeks in length, study duration
does not seem to be a limiting factor.
Since 2015, the utility of laboratory mice for investigations
on human microbiota has been subject to critical review in 3
articles [8-10]. In documenting advantages and disadvantages
of mice compared to humans, Nguyen et al [9] list several
advantages: the model allows for invasive intervention to
investigate causal relationships; genetic information is robust
and well curated; the model has a relatively short life span;
mice are omnivorous; and the overall structure of the
gastrointestinal tract is somewhat similar to humans. More-
over, the use of inbred mice strains reduces interindividual
variation in experimental groups, and environmental condi-
tions can be controlled. Conversely, although the overall
gastrointestinal tract is similar, the relative size of its organcomponents differs, as does villus architecture. Unlike
humans, rodents ferment indigestible substrates in the
cecum, whereas fermentation in humans happens primarily
in the colon. Humans and rodents also differ in stool
consistency; rodent stool is typically drier than human,
suggesting differential osmotic regulation in the colon.
Importantly, the cross talk between the microbiota and host
is host specific, and thus, a human microbiome may not be
recapitulated in total in mice [9]. In a second review,
Hugenholtz and de Vos point out that, although many genera
are shared between rodents and humans, only 4% of the
bacterial genes share considerable identity [8]. It is likely that
basal rodent diets account for some of these differences
between mice and human microbiomes. Compounding this
problem, inbred mice have been shown to have a different
and less resilient microbiome compared to wild mice.
Interestingly, in a study by Rosshart et al [11], C57BL/6
mouse embryos were transferred into wild mice to recapitu-
late the wild mouse microbiome in a laboratory setting. In
subsequent studies, the resulting mice more closely resem-
bled humans in terms of immune phenotype compared to
conventional mice.
One factor driving interest in the microbiota and health is
a series of seminal studies that showed an obese phenotype
could be induced in a germ-free reared mouse via transplan-
tation of microbiota from obese individuals [12-14]. This work
led to the characterization of an “obese microbiome” typified
by an increased Firmicutes to Bacteroidetes ratio, reduced
diversity, and an increased metabolic capacity to extract
energy from the diet [14]. Recently, Dalby et al showed that
obesity in high-fat–fed mice is driven primarily by the fat in
the diets, not by increased energy harvest due to changes in
the microbiome and cecal fermentation [15]. Although many
factors have been shown to affect the composition of the
microbiota, a recent study by our group found that diet is a
primary factor [16]. In the study, the native microbiome of
mice was depleted using a cocktail of broad-spectrum
antibiotics. Mice then were inoculated with human microbi-
ota from either lean or obese donors. Mice were fed either the
standard AIN93G diet; the total Western diet, which is a basal
diet that models typical micro- and macronutrient intakes
based on National Health and Nutrition Examination Survey
(NHANES) data [17]; or a diet-induced obesity diet (diet with
45% of energy as fat). Interestingly, after 22 weeks, diet had
the largest impact on the microbiota composition and body
weight gain, although some notable, significant differences
remained among mice that received the microbiota of
different donor types.
Collectively, these data suggest that the choice of basal
diet used in preclinical studies to investigate connections
between the gut microbiome and systemic health or disease
deserves careful consideration. Moreover, to improve trans-
latability of preclinical studies, it is also critical to use basal
diets that are relevant to patterns of human nutrition. We
performed a literature search to identify preclinical studies
that examined the impact of food matrix components
including fiber, protein, lipid oxidation products, and emul-
sions and their effects on gut and metabolic health. In this
review, sources of variation between human diets and basal
diets used in rodent studies and the possible implications of
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to humans will be examined.2. Basal rodent diets and fiber
The composition and metabolic activity of the gut microbiota
influence many aspects of health. Consequently, there is
interest in dietary strategies to improve health via modulat-
ing the microbiota. Mice are the most common model
organisms used to study the microbiota, yet the translational
relevance to humans has been questioned [8-10]. Dietary fiber
has a large impact on the microbiota composition and
metabolic activity via provision of fermentable substrates
[18]; yet, to date, there has been very little attention paid to
modeling the fiber composition of rodent diets to that of
humans. Thus, there is a critical need to establish how the
microbiota of mice responds to the range of human dietary
fiber intakes and whether the changes are consistent with
health benefits provided by dietary fiber in humans.
According to data from NHANES, the average American
diet contains 60% of the Adequate Intake (AI) of dietary fiber
[19,20] recommended by the Institute of Medicine (IOM). The
AI for fiber is scaled to energy and is 14 g per 4184 kj, which
often is simplified to 25 g/d for women and 38 g/d for men.
According to What We Eat in America, the 2015-2016 NHANES,
Americans eat an average of 16.7 g of dietary fiber per 8807 kj
(~8 g/4184 kj [21]. In 2001, the Food and Nutrition Board of the
Institute of Medicine set the AI for total fiber at 14 g/4184 kj
[22], which was based on a number of prospective cohort
studies that showed significant reductions in the risk for
coronary heart disease [23-25] and type 2 diabetes [26,27] in
individuals consuming the most fiber. It is estimated that
only ~5% of Americans consume the AI for fiber [28], whereas
the average intake (from NHANES) is only 60% of the
recommended level. Fiber intakes have increased about 20%
since the 2001-2002 NHANES survey yet are still far less than
levels shown in prospective cohort studies to reduce the risk
of heart disease and diabetes. Evidence from prospective
cohort studies and randomized clinical trials suggests that
increasing fiber intake reduces gut and systemic inflamma-
tion and provides protection against the development of
coronary heart disease and type 2 diabetes (T2D) [29-31]. In a
recent meta-analysis, the risk for a number of clinical
outcomes, such as coronary heart disease and T2D, was
reduced when the fiber intake was between 25 and 29 g/d [32].
Interestingly, dose-response curves from this study indicated
that higher intakes might even provide more protection.
Although the evidence that dietary fiber promotes gut and
metabolic health is well documented in humans, the mech-
anisms via which this is done are not well known. The
difference between recommended and actual intakes of fiber
has been called the fiber gap [33]. Evidence-based strategies to
address the fiber gap are needed. It has been suggested this
may be achieved via increased consumption of foods with
high intrinsic fiber levels, as well as consumption of proc-
essed foods where fiber is increased via supplementation of
natural or synthetic fibers [34]. It has been shown in humans
that diet rapidly changes the structure and activity of the
microbiota [35]. Compared to a diet primarily composed ofanimal products, a diet rich in plant polysaccharides in-
creased the abundance of carbohydrate- metabolizing mi-
crobes including Rosburia, Eubacterium rectale, and
Ruminococcus bromii. In humans, dietary fiber at the AI of the
IOM has been shown to alleviate T2D via a mechanism
involving the microbiota [36]. Zhao et al fed type 2 diabetic
patients diets that contained either 15 or 37 g/d dietary fiber
for 12 weeks. The high-fiber diet caused a selective increase
in microbes that produce SCFAs and was associated with
lower hemoglobin A1c and increased glucagon-like peptide-1
production. For mice to be valuable surrogates for human
microbiota research, a similar phenotype should result from
feeding mice diets with fiber levels at the IOM AI.
A shortcoming of semipurified diets for chronic-disease
and microbiome research is that the fiber source is cellulose.
Semipurified rodent diets do not contain an adequate
diversity of fermentable substrates, and over multiple gener-
ations, the microbiomes of mice fed these diets progressively
lose diversity [18]. In 1980, Wise and Gilburt noted that
semipurified rodent diets are analogous to Western diets,
whereas chow is more like an unrefined African diet [37].
Interestingly, in 2017, De Filippo et al compared the
microbiomes of children from the African nation of Burkina
Faso who consumed traditional diets rich in cereals, legumes,
and vegetables to Italian children who consumed Western
diets [38]. The fecal SCFAs were roughly 3-fold higher in the
African children consuming traditional diets compared to the
urban Italian children. Using Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States, they
inferred functional differences in the microbiomes between
the children and found that the rural African microbiomes
were enriched in genes for complex carbohydrate metabo-
lism. A possible link between low fiber intakes, gut carbohy-
drate metabolism, and gut inflammation was revealed in
gnotobiotic mice by inoculating them with a defined human
microbiota of 16 fully sequenced species [39]. Mice were fed
either a chow diet with ~50 g fiber/1000 kcal or a semipurified
diet that contained ~20 g cellulose/1000 kcal. Compared to the
microbiome of mice fed the fiber-rich diet, the microbiome of
mice fed the diet with only cellulose was enriched in the
metabolic capacity to consume host-derived mucins. This
change was also associated with a degraded mucin layer and
closer proximity of the luminal microbes to the intestinal
epithelium. Mice with degraded mucin layers also had
increased fecal lipocalin, a neutrophil protein associated
with low-grade inflammation and decreased colon length.
Others have also shown that defined diets containing
cellulose cause a loss of cecal and colonic mass as compared
to chow diets and that this effect can be ameliorated by
replacing cellulose with inulin [40].
The use of different fiber types in formulating experimen-
tal diets for preclinical models of chronic disease often leads
to changes in the disease phenotype and the composition
and/or function of the intestinal microbiome. Moen et al [41]
fed APCMin/+ mice the AIN93M diet with cellulose, inulin, or
brewers spent grain as the fiber source at either 5 or 15% wt/
wt of the diet. Mice fed inulin as the fiber source had a
lowered colonic tumor burden and decreased cecal α diversity
compared to the other treatments. Moreover, the fiber type
appeared to drive distinction of the gut microbiomes and
Table 1 – Example of a high-fiber diet suggested by the
IOMa




Breakfast Grapefruit (1/2 medium) 159 1.4
Banana (1 medium) 456 2.8
Cereal, shredded oats (1 cup) 469 3
English muffin (white, 1
whole)
561 1.5
Margarine (2 tsp) 285 0
Milk, 1% (1 cup) 427 0
Snack Crackers, whole wheat (6
each)
456 0.9
Cheddar cheese (1.5 oz) 716 0
Juice (3/4 cup) 326 0.4
Lunch Tossed salad (1 cup) 67 1.5
Salad dressing (1 tbs) 276 0
Chili with beans and beef (1
cup)
1142 6.5
Cornbread (1 piece) 724 1.3
Grapes (1/2 cup) 142 0.8
Fig bar cookies (2) 238 1.5
Milk, 1% (1 cup) 427 0
Dinner Salmon in soy sauce (3.5 oz) 707 0.2
Rice with vegetables (3/4
cup)
699 1.4
Broccoli (1-1/2 cup) 167 4.4
Roll, whole wheat (2
medium)
740 5
Ice cream (1/2 cup) 410 0.3
Snack Carrots, raw (12 medium
baby)
213 3.6
Spinach dip (2 tbs) 243 0.4
Turkey sandwich 1435 1.2
Cola 640 0
Total 12878 38.1
a Adapted from [19].
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groups. Dietary fiber has also been studied in relation to
colitis. Mice challenged with dextran sodium sulfate and fed a
semipurified diet had increased colitis severity compared to
chow-fed controls, and this phenotype could not be rescued
by replacing cellulose in the semipurified diet with inulin [42].
Using an IL-10 receptor antibody colitis model, Singh et al [43]
fed mice either diets containing exclusively cellulose or diets
supplemented with inulin or pectin. They reported that
pectin, but not inulin, suppressed colitis in this model, and
this effect was mediated through decreased butyrate produc-
tion. Mice fed the inulin-containing diet had increased
butyrate-producing bacteria, including γ-Proteobacteria.
Dietary fiber manipulations have also been used to study
effects on obesity in the context of high-fat diets. In a study
that compared inulin, cellulose, and guar gum as fiber sources
in high-fat diets, Weitkunat et al [44] reported that inulin
protected against weight gain compared to the cellulose and
guar gum treatments. The fiber manipulations also caused
differences in the gut microbiomes. Mice fed the inulin diet
had increased Bifidobacterium animalis, whereas the guar gum–
fed mice had increased Bifidobacterium pseudolongum. Drew et
al [45] compared a traditional high-fat diet with cellulose as
the fiber source to high-fat diets with 5% of the cellulose and
5% of cornstarch replaced with β-glucan, pectin, inulin, or 3
different inulin SCFA esters (inulin acetate ester, inulin
propionate ester, inulin butyrate ester or a combination of
inulin propionate ester and inulin butyrate). Mice were fed the
experimental diets for 8 weeks. Mice fed the traditional high-
fat diet gained more weight and had increased fat mass
compared to all of the high-fat treatments with added fiber,
suggesting a protective effect of inulin, β-glucan, pectin, and
inulin SCFA esters against obesity. However, despite having
similar effects in terms of obesity prevention, all pairwise β
diversity comparisons among inulin, pectin, and β-glucan
treatments revealed distinct microbiomes, suggesting that
the antiobesity properties of these diets were independent of
the microbiome composition.
Taken together, these studies suggest that fiber is not an
inert dietary component and can have large effects on disease
endpoints commonly assessed in preclinical studies. Dietary
fiber also plays amajor role in shaping themicrobiome. These
studies also suggest that semipurified diets that contain
cellulose such as the AIN93G series may exacerbate chronic
disease. Therefore, care must be taken in interpreting the
microbiome and disease endpoint results of preclinical
studies that use different fiber sources, that is, chow diets vs
semipurified diets containing cellulose.
The AI for fiber set by the IOM does not specify specific
fiber types, and thus, it is not clear how to model human fiber
intakes in rodent semipurified diets [19]. However, one
strategy to address this would be to determine the fiber
content of a recommended 1-day meal plan. Table 1 shows a
1-day meal plan included in the IOM report that provides 38 g
of dietary fiber. In 1997, Marlett and Cheung [46] published a
fiber profile for 228 commonly consumed foods. For each
food, the soluble and insoluble fiber content was determined.
For soluble fiber, further chemical tests were run for hemi-
cellulose, pectin, and β-glucan. For the insoluble fiber, the
cellulose, hemicellulose, pectin, and lignin contents wereevaluated. Using this database and the food list in Table 1, we
determined that the fiber profile in the 1-day diet is
approximately 80% insoluble and 20% soluble. The fiber in
this proposed diet was approximately 4% β-glucan, 15%
pectin, 37% hemicellulose, 29% cellulose, and 15% lignin.
Although cellulose, pectin, and oat-derived β-glucan are
commercially available, there are no purified sources of
hemicellulose or lignin. However, there are reports of an oat
fiber product composed primarily of cellulose (70%), hemicel-
lulose (25%), and lignin (5%) [47]. Although it is not currently
possible to precisely model the recommended IOM intake for
mice currently, a mix of pectin, β-glucan, and the oat fiber
listed above should be an improvement on cellulose alone.3. Food processing and the microbiome
In terms of providing substrates to the gut microbiome,
human diets are much more complicated than the sum of
their macro- and micronutrient components. Cooking and
processing of food can lead to the introduction of protein and
lipid oxidation products into the diet. Moreover, dietary
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aspects of processed foods. All of these food matrix factors
can independently affect health and the composition of the
microbiome but are rarely considered in preclinical disease
models despite being common components in human diets.
In a recent investigation by Johnson et al, human volunteers
kept 24-hour food records, and their gut microbiomes were
tracked for 17 days. The dietary records were then used to
predict changes to the microbiome. They reported that
conventional methods of describing foods based on nutrients
were a poor predictor of the microbiome composition
compared to a whole food-based, hierarchical tree of foods
developed for the study [48]. This observation suggests that
the food matrix is more important for shaping the
microbiome than the micro- and macronutrient content of
the diet. Aside from the nutrient content, varying methods of
food processing or preparation may also impact the compo-
sition and/or function of the gut microbiome. For example,
one study explored the impact of consumption of raw or
cooked meat and tubers on the gut microbiome in mice [49].
Researchers noted that differences in the mice microbiomes
were evident when comparing raw vs cooked tubers but not
raw vs cooked meat. Also, α diversity was lower in mice fed
raw tubers compared to cooked tubers, whereas Bacteroidetes
were increased [49].
The Maillard reaction, which is also known as nonenzymatic
browning, is the result of the reaction between a reducing
sugar and a free amino group of a protein, or nucleic acid. The
Maillard reaction is very important in foods because it
contributes to the formation of flavors and golden-brown
color. However, it is a very complicated reaction, and some of
the products may be toxic. In addition, the Maillard reaction
may reduce the nutritional value of foods by destroying
essential amino acids, such as lysine. Maillard reaction
products (MRPs) usually are classified into 3 groups: early
MRPs, advanced MRPs, and melanoidins [50].
N-carboxymethyl-lysine (CML) is an advanced MRP that is
typicallymeasured in food, and the overall load of dietaryMRPs
is often inferred from the CML content. Animal studies have
shown that high intakes of MRPs result in increased plasma
levels of CML, andup to 30%of dietary CML is absorbed from the
gut [51]. Since 2002, a number of published studies in mice and
rats have shown that diets high in MRPs (as specifically
measured by CML)may promotemany of the chronicmetabolic
diseases common in the United States such as diabetes and
nonalcoholic fatty liver and cardiovascular diseases [52]. Diets
with high CML loads have been shown to promote glucose
intolerance [53-55], liver inflammation [54,56,57], and cardiac
inflammation [58] when compared to diets lower in CML. In
addition, a recent study found that a diet high in MRPs was
associated with negative changes in gut health including an
increase in inflammation, a reduction in fecal SCFAs, and a
reduction in the diversity of the fecal microbiome [59]. In that
study, ratswere fedanAIN93G-baseddiet containing either 2.79
or 14.43 mg CML/kg diet for 18 weeks. Rats fed the high-CML
diets had decreased α diversity and distinct cecal microbiomes
when compared using β diversity analysis. Specifically, the
high-CML group had increased Proteobacteria, Allobaculum,
Bacteroides and decreased Alloprevotella and Ruminococcaceae.
The high-CML–fed rats also had higher levels of cecal ammoniasuggesting increased protein fermentation. Yet, other studies
with MRPs have suggested they may have at least some
potential to improve gut health. Anton et al [60] used a colitis
model in mice and provided them with a control diet and
experimental diets with MRPs produced via 2 methods. Mildly
heated pellets were autoclaved at 120°C for 30 minutes, and the
highly heated pellets were baked at 150°C for 15 minutes after
pellets were rehydrated with 30% (wt/wt) water. Both the mild-
and high-heat pellets had significantly more CML than the
control pellets, and the high-heat pellets had more soluble
melanoidins than both the mild-heat and control pellets. Mice
were providedwith 3%DSS in the drinkingwater for 8 days, and
the inflammatory response was subsequently measured in the
colon. Interestingly, the high-heat pellets, rich in melanoidins,
reduced the macroscopic damage score and colon shortening
and decreased myeloperoxidase activity.
A few small, randomized, crossover studies with dietary
MRPs have been conducted in humans, and 3 meta-analyses
have compiled the data in an effort to distill the relevant
effects on health [61-63]. Overall, themain findings were that
increasing MRPs in the diet is associated with mild yet
significant systemic inflammation (as measured by plasma
tumor necrosis factor-α) as well as elevated oxidative stress
(asmeasured by plasma 8-isoprostanes). Seiquer et al [64] fed
20 male adolescents diets containing either 6.62 or 15.72 mg
CML/100 g protein and rats a high- or low-CML diet (2.2 vs
12.46 mg CML/kg diet). Lactobacilli were lower in the high-
CML diets for both humans and rats and were the only taxon
that changed in the same direction in response to CML in
both humans and rats. Taken together, the rodent and
human studies listed above suggest that it would be
beneficial to reduce intake of MRPs, yet there is a significant
methodological flaw across these studies that limits our
ability to specifically implicate MRPs. This flaw is due to the
method by which the MRPs were introduced into the diet. For
example, in all the rodent studies, MRPswere produced in the
diet by heating the diet pellets at elevated temperatures (125-
160°C) for specific time periods (30 minutes to 3 hours), and
the control diets were unheated diet pellets. In addition to
inducingMRP formation, these time-temperature treatments
also induce thermal destruction of vitamins and oxidization
of the fat in the diet. Consequently, it is currently unclear to
what extent themetabolic dysregulation in these studies can
be attributed to MRPs specifically vs the combination with
oxidized lipids and decreased vitamin intakes.
In food systems, lipid oxidation affects food quality and
the acceptance by consumers [65]. Deleterious changes in
foods caused by lipid oxidation include development of off-
flavors, and loss of color, nutrition, and functionality.
Oxidation consists of 3 stages: initiation (the formation of
radicals), propagation (free-radical chain reactions), and
termination (the formation of nonradical products). The
production of free-radicals generates cytotoxic compounds
and co-oxidizes vitamins. In the food industry, the oxidation
status of food fats is typically determined by 2measurements,
peroxide value (PV), and anisidine value (AV). PV measures
the first step of lipid oxidation (ie, the presence of lipid
hydroperoxides), and AV measures the aldehyde break-down
products of the lipid hydroperoxides. As a fat becomes more
oxidized, the PV starts to decline, and the AV increases. A high
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oxidation products and vice versa.
The primary lipids that become oxidized in foods are the
essential polyunsaturated fatty acids (PUFAs), such as linoleic
acid and linolenic acid, as well as the long-chain highly
unsaturated PUFAs arachidonic and docosahexaenoic acids
[66]. The rate of oxidation of these fatty acids depends on the
degree of unsaturation, and the more highly unsaturated the
fatty acid is, the faster the reaction occurs. Oxidation of PUFA
leads to the formation of hydroperoxides (initiation stage),
and depending on the conditions, these may undergo
fragmentation to produce reactive aldehyde products (pro-
motion stage), which covalently bond with nucleophilic
groups in proteins and nucleic acids. This results in a broad
range of protein and DNA adducts and promotes oxidative
stress [67]. Consequently, depending on its composition and
processing history, a food fat may have a different profile of
oxidation products. For example, a PUFA-rich oil held at room
temperature for a long period will be rich in hydroperoxides
(measured by PV) yet low in reactive aldehydes (measured by
AV). Conversely, some fats are oxidized at very high temper-
atures (ie, 175°C) when used to fry foods, and such “thermally
abused” oils tend to be low in hydroperoxides and rich in
reactive aldehydes. Although the toxicity of the aldehydes
produced in the latter stages of lipid oxidation is well
characterized, it has been suggested more recently that the
lipid hydroperoxides, common in oils oxidized at lower
temperatures, may decompose in the digestive tract and
promote gut inflammation and dysfunction [68]. In the last
century in the United States, dietary intake of linoleic acid
(18:2n6; omega-6) has increased from 2.79% of energy to 7.21%
of energy, whereas consumption of linolenic acid (18:3n3;
omega-3) has increased from 0.39% to 0.72% of energy [69].
Many foods are now supplemented with the long-chain
omega-3 PUFA. In addition, many foods in the Western diet
are consumed either heated or fried, which also promotes
lipid oxidation [66]. Thus, the Western diet contains signifi-
cant quantities of oxidized fatty acids, oxidized cholesterol,
and aldehyde breakdown products [70].
In experimental animal models and humans, consump-
tion of oxidized fats, compared to control diets, has been
shown to promote harmful systemic physiological responses
such as oxidative stress, endothelial dysfunction, and
hypertension [71]. In addition, the oxidation products of
dietary fats have been implicated in the etiology of many
chronic Western diseases such as cancer and cardiovascular
disease [72]. Oxidized dietary fats also promote glucose
intolerance via mechanisms involving oxidative stress [73].
Chiang et al found that adding oxidized fats to the diets of
mice caused a decrease in glucose tolerance, as measured by
an oral glucose tolerance test, and the effect was due to
decreased insulin production in the pancreas [74]. Interest-
ingly, increasing the vitamin E content of the diet prevented
the oxidative stress and subsequent glucose intolerance.
Lastly, oxidized dietary fats also appear to promote intestinal
oxidative stress and inflammation, again via an oxidative
stress mechanism [71,75].
Although endogenous lipid peroxidation is a well-known
factor in the development of chronic disease, the designs of
the studies cited above involve comparison of oxidized oils tounheated controls and effects on chronic disease. In many of
the animal studies, the oils were subjected to severe thermal
treatments, and the levels of oxidation products are probably
much higher thanwould be consumed by humans. Although,
in some cases, care was taken to gently oxidize the oils, and
significant effects were nonetheless reported [75]. However,
deep-fried safflower or olive oil does adversely affect
endothelial function in humans [76], and in a Spanish cohort,
where olive and sunflower oils are commonly used for deep-
frying, consumption of fried foods was not associated with
heart disease or all causes of mortality [77].
There have been very few carefully controlled studies
examining oxidized fats on the microbiome. In a large-scale
population-based study, fried food consumption was corre-
lated with lowered α diversity, whereas foods such as raw
vegetables, eggs, fish, and raw fruit were associated with
higher α diversity [78]. Zhou et al [79] compared the effects of
nonheated vs deep-fried canola oil on the microbiomes of
rats fed a chow diet. In this study, 1.5 mL of either oil was
gavaged daily for 6 weeks. Rats treated with the control or
deep-fried oils had distinct microbiomes as assessed by β
diversity analysis, but there were no differences in α
diversity. When Linear discriminant analysis effect size
(LEfSe) analysis was performed, the top discriminating
taxon for the deep-fried oil treatment was an enrichment of
Allobaculum, Lactobacillus, Bacteroides, Oscillospira, and
Bifidobacterium spp relative to the control oil. These studies
suggest that the oxidation of fat, a common byproduct of
thermal processing, affects the microbiome independent
from protein oxidation products; however, how these
changes to the microbiome might affect chronic disease risk
in humans is not known.
Emulsions are heterogeneous systems composed of water
and an oil phase stabilized by an emulsifier such as whey
protein or polysorbate 80 (P80). Emulsions can be broadly
classified into oil-in-water emulsions, where the oil phase is
dispersed in the form of droplets in the water phase, and
water-in-oil emulsions, where the water phase is dispersed
in the continuous oil phase. Examples of oil-in-water food
emulsions include dressings, cream, and milk, whereas
examples of water-in-oil emulsions include butter, marga-
rines, and spreads. Not only are emulsions used in food
systems to allow for the coexistence of 2 immiscible phases,
but they are also commonly used to deliver flavors or
nutrients. In the case of a liquid emulsion, these compounds
can be delivered in a beverage, spread, or dressing.
In foods, emulsifiers are often used with texture
modifiers and weighting agents to modulate food structure,
and all 3 food additives may affect the microbiome via
direct and indirect mechanisms. In a recent review, Halmos
et al [80] covered the most common emulsifiers and listed
areas of concern as well as gaps in scientific knowledge in
this field. According to the review, the 7 most commonly
used additive emulsifiers are carboxymethyl cellulose
(CMC), P80, lecithin, mono- and diglycerides, stearoyl
lactylates, sucrose esters, and polyglycerol polyricinoleate.
Some of these emulsifiers, such as the mono- and
diglycerides, are commonly found in foods and should be
digested and absorbed in the small intestine. Others, like
CMC, resist digestion.
Fig. 1 – Effects of food matrix components on the gut microbiome composition, associated health parameters, and implications for
preclinical chronic diseasemodels. (A and B) Cellulose as the only source of fiber in semipurified diets promotesmucin degradation
[39,40] and promotes colitis [42]. (C) Moreover, diets with fiber sources other than cellulose can protect against diet-induced obesity
and insulin resistance [44,45]. (D) Mice fed semipurified diets containing cellulose have dissimilar microbiomes to mice fed
polysaccharides-rich diets in chronic disease models [15], and diets containing only cellulose cause a loss of taxa over generations
[18]. Components typically found in human diets but not in basal rodent diets such as emulsifying agents and protein or lipid
oxidation products can also affect colitis, chronic disease, and the gut microbiome. Commonly consumed emulsifying agents used
in human diets have been demonstrated to (E) increase colitis [83,85,86], (F) promote metabolic syndrome [83], and (G) cause
changes to the gut microbiome [83,85-87]. Thermal processing of food can lead to the formation of protein and lipid oxidation
products not found in rodent diets. Protein oxidation metabolites have been shown to (H) induce diabetes [53], nonalcoholic fatty
liver [54,56,57], and cardiovascular disease [58] but (I) decrease colitis in animal models [60] and (J) can change the gut microbiome
composition [59]. Lipid oxidation products have been shown to (K) promote aberrant glucosemetabolism [73,74] and (L) change the
gut microbiome composition [79.].
7N U T R I T I O N R E S E A R C H 7 8 ( 2 0 2 0 ) 1 – 1 0Recently, the effects of dietary emulsifiers on the gut
microbiome and gut health have been investigated. For
instance, when obese human subjects consumed beverages
containing fat in either an emulsified or nonemulsified
form, chylomicron-endotoxemia kinetics differed according
to the presence of emulsified fat [81]. In this study, the
emulsions were formed directly in milk, and thus, the
emulsifying agent was milk protein and not one of the
additives described above. Similar to the mono- and
diglycerides, the milk proteins which stabilized the emul-
sions should be digested in the small intestines, and thus,
it is not clear how the physical structure of the emulsion
was responsible for the differential endotoxin absorption.
Within a specific class of emulsifiers, the specific chemical
composition may affect the gut barrier and systemic
metabolism. For example, Lecomte et al [82] fed mice
high-fat diets with emulsions prepared with either soybean
lecithin or milk polar lipids. Mice fed the diets with milk-
derived polar lipids had an improved gut barrier which was
attributed to increased goblet cells. Mice in the soybean
lecithin had increased white adipose tissue and adipose
tissue inflammation.Chaissang and colleagues [83] demonstrated that inclusion
of emulsifying agents into mouse diets or drinking water had
detrimental effects on several parameters associated with
metabolic syndrome and unfavorably changed the gut
microbiome. Both CMC and P80 treatment reduced α diversity
and increased the relative abundance of several mucolytic
OTU including Ruminococcus gnavus and Akkermansia
muciniphilia as well as inflammation-promoting
Proteobacteria. Inclusion of P80 to the drinking water at a
concentration of 1% wt/vol resulted in intestinal inflamma-
tion, a distinct microbiome, and reduced α diversity compared
to control mice. Moreover, mice in the P80 treatment had
increased energy intake, fat mass, and impaired glycemic
control relative to controls. Interestingly, germ-free mice
seeded with bacteria from mice treated with P80 had
increased adiposity and impaired glycemic control, suggest-
ing that these effects were mediated through changes in the
microbiome. Levels as low as 0.1% of P80 caused observable
low-grade inflammation and 0.5% resulted in dysglycemia. In
a subsequent study by the same group [84], P80 was again
included in drinking water (1% wt/vol) to determine if
inclusion exacerbates inflammatory driven colorectal cancer.
8 N U T R I T I O N R E S E A R C H 7 8 ( 2 0 2 0 ) 1 – 1 0Mice in the P80 treatment had increased gut inflammation, a
higher load of bioactive lipopolysaccharide, and a 3-fold
increase in tumor surface area compared to controls. Inter-
estingly, when germ-free mice were conventionalized with
altered Schraedler flora, a defined 8-strain microbiome, CMC
and P80 treatment did not affect the microbiome or markers
of metabolic syndrome contrary to studies with complex
microbiomes. Moreover, when mice were conventionalized
with emulsifier treated bacteria from the ex vivo mucosal
simulator of the human intestinal microbial ecosystem,
recipients gained more weight and had increased fasted
glucose and shorter colons compared to mice
conventionalized with control mucosal simulator of the
human intestinal microbial ecosystem bacteria. These studies
suggest that dietary emulsifying agents such as P80 increase
intestinal inflammation that, in turn, increases adiposity and
insulin resistance and that these changes are mediated via
changes to the gut microbiome and not from the emulsifiers
acting directly on the gut architecture.4. Conclusions
Although mice are the most commonly used species for
microbiota studies, the translational relevance of preclinical
studies using mice as models for studying the intersection
of nutrition and the microbiome as pertains to health and
disease in humans is unclear. Although individual food
matrix components have been tested in rodent models as
reviewed herein, the effects of all of these factors combined
on the microbiome in preclinical models of chronic disease
are unclear, representing a critical knowledge gap. Future
research to address this issue could increase the translat-
ability of these models.
Unless mice are provided with diets that reflect actual
human intakes of fiber and possibly other components, such
as oxidized protein and fat or emulsifiers, and the resulting
phenotypes are characterized, translatability of preclinical
models in studies focused on diet and the gut microbiome to
human populations may be hampered because all of these
components can independently affect chronic disease and
the microbiome in mouse models (Fig. 1). Semipurified rodent
diets only contain cellulose as a source of dietary fiber, which
promotes a microbiome that degrades the mucin barrier,
promotes intestinal inflammation, and changes to the
microbiome. A possible first step to improve the translatabil-
ity of microbiota/chronic-disease models would be to use a
diverse portfolio of fiber in semipurified diets that reflect
human intakes instead of cellulose. This approach would
address an important source of variability in the gut
microbiome between humans and experimental animals.Acknowledgment
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